-
We detected your language preference as English. Would you like to switch to the English version for a better experience?
Switch to English
Stay here
Newly disclosed agreements between the U.S. Department of Health and Human Services (HHS) and Pfizer and Eli Lilly indicate that the Trump administration's “most favored nation” (MFN) drug-pricing strategy extends beyond reducing selected U.S. prices. Pfizer's agreement contains a provision under which HHS is to receive a portion of the company's incremental net revenue generated by higher prices for certain medicines outside the United States. The exact revenue-sharing percentage, covered products and other commercial terms remain redacted.
The disclosures provide the clearest public evidence to date that the administration's effort to shift more of the cost of pharmaceutical innovation to foreign markets can include a direct financial mechanism involving the U.S. government. Similar language has appeared in public securities filings from Merck and Gilead, although the precise mechanics of those arrangements are not publicly available.
GuideView's assessment is that the documents materially broaden the understanding of MFN agreements: the policy framework is not solely a U.S. price-discount mechanism, but also a trade and revenue-allocation strategy whose ultimate financial impact remains difficult to quantify because key contractual provisions are unavailable.
Documents released following a Freedom of Information Act (FOIA) dispute provide new details on the agreement between Pfizer and the Trump administration. Public Citizen obtained copies of the Pfizer and Eli Lilly agreements after pursuing disclosure through FOIA; the organization said the administration provided the documents only after litigation. Both agreements are substantially redacted, limiting the ability to determine their complete economic terms.
The Pfizer agreement contains a section stating that the company will share with HHS a redacted portion of the “net increased net revenue” it realizes from sales of covered products outside the United States when that additional revenue results from higher net prices abroad. The provision indicates that the mechanism is tied specifically to incremental revenue generated by increased international pricing, rather than merely requiring Pfizer to transfer existing overseas earnings to the United States.
“Pfizer agrees to share with HHS [redacted] portion of the net increased net revenue that Pfizer realizes from sales of the ex-U.S. version of Covered Products resulting from increased net prices of such ex-U.S. version of Covered Products.”
The released contract does not identify the percentage payable to HHS, the complete list of affected medicines, or other provisions necessary to calculate the potential value of the arrangement. Bloomberg reported that the agreement provides for HHS to receive a portion of increased revenue if Pfizer succeeds in charging higher prices overseas.
Publicly available records indicate that the definitive HHS-Pfizer agreement was signed on February 23, 2026, while the original Pfizer administration agreement was announced on September 30, 2025. Public Citizen's released-document archive identifies the February agreement as the definitive agreement.
Eli Lilly's agreement contains a section titled “Return increased revenues in specified countries to American patients and taxpayers.” However, the released document is even more heavily redacted, preventing a detailed comparison with Pfizer's revenue-sharing mechanism. Public Citizen's document archive identifies Lilly's definitive HHS agreement as also dated February 23, 2026.
Consequently, the available documents do not establish whether Pfizer and Lilly face identical revenue-sharing obligations, whether the arrangements apply to the same categories of products or countries, or what portion of incremental foreign revenue ultimately reaches the U.S. government or American patients.
The distinction is important because the White House has described the broader policy as an effort to make foreign countries contribute more toward the cost of pharmaceutical innovation, while the contracts suggest that at least some of the resulting incremental revenue can be directed through a formal government-linked mechanism.
The administration's MFN agreements have been negotiated individually with major pharmaceutical manufacturers. According to a White House fact sheet published August 31, 2026, the administration said it had agreements with 27 companies, including Pfizer, Eli Lilly, Merck and Gilead Sciences. The White House has characterized the agreements as part of a broader effort to lower prescription-drug costs for Americans while encouraging higher prices in foreign markets.
The policy therefore operates through several interconnected mechanisms. Depending on the agreement, companies may be required to provide MFN-linked pricing in the United States, offer direct-to-consumer discounts, participate in Medicaid pricing initiatives, make domestic manufacturing commitments or accept conditions relating to international prices and revenue.
The White House has argued that the policy is intended to prevent U.S. patients from carrying a disproportionate share of global pharmaceutical costs. A White House spokesperson, Kush Desai, said the foreign-revenue provisions are intended to ensure that incremental revenue created by higher prices abroad benefits American patients rather than solely the drug manufacturers.
The Pfizer disclosure is significant partly because similar concepts have appeared in corporate securities filings. Merck's 2026 quarterly filing states that the company agreed to “repatriate and share with the Federal government a portion of foreign revenue” received as a result of the government's successful trade-policy efforts. Merck's filing also describes MFN pricing commitments and a three-year delay of Section 232 tariffs tied to U.S. manufacturing investment.
Gilead's filings provide another example. The company disclosed that, under its December 2025 agreement with the administration, it would return a portion of increased international revenues to the United States if the U.S. government succeeded in increasing drug prices abroad. Gilead's filing also describes MFN pricing for selected Medicaid products and future launches, as well as a new direct-to-patient price for Epclusa.
These corporate disclosures do not establish that all 27 MFN agreements use identical revenue-sharing structures. They do, however, show that the concept is not unique to the newly disclosed Pfizer contract.
The principal limitation on assessing the agreements is the volume of information that remains confidential. Public Citizen said the Pfizer and Lilly documents contain extensive redactions, including information relevant to pricing, products, enforcement and other commercial terms. Its analysis also identifies unresolved questions concerning termination rights, compliance remedies and the interaction between individual MFN agreements and federal pricing programs.
The Washington Post separately reported that the agreements contain broad confidentiality provisions and that key elements of the administration's commitments were not publicly disclosed when the companies initially announced their arrangements.
For industry participants, the lack of disclosure means that headline claims about aggregate savings cannot readily be reconciled with the contracts' complete financial obligations. The White House has continued to characterize the MFN program as producing substantial savings for U.S. patients and taxpayers, while independent analysis remains constrained by the limited availability of underlying contractual data.
GuideView observes that the newly disclosed Pfizer language changes the way the MFN agreements can be understood from an industry-structure perspective. The policy is not simply a conventional price-negotiation exercise in which U.S. purchasers receive lower prices. It combines domestic price intervention with international trade policy and, in at least some cases, a mechanism for allocating incremental foreign revenue to the U.S. government.
For pharmaceutical companies, that structure creates a new commercial variable: international pricing decisions can become directly relevant to obligations under U.S. government agreements. For policymakers, it creates a potential channel through which the financial gains from higher overseas prices can be redirected toward U.S. patients or taxpayers. The actual magnitude of that transfer, however, cannot yet be independently established because the released contracts omit critical percentages, product lists and calculation methodologies.
GuideView also notes a broader strategic implication for global pharmaceutical pricing. If MFN agreements become a durable component of U.S. trade and health policy, multinational manufacturers may face greater pressure to reassess the traditional differential-pricing model across developed markets. The effect could extend beyond individual drug discounts to negotiations with foreign governments, launch sequencing, market access and the allocation of global pharmaceutical revenues.
The key industry question is therefore not simply how much U.S. prices fall, but how the agreements redistribute the economic burden of pharmaceutical innovation across countries and between manufacturers, governments and patients. Until the remaining contractual terms become public, the precise balance of those effects remains unresolved.
Source context: Publicly released Pfizer and Eli Lilly MFN agreements obtained through FOIA; U.S. Securities and Exchange Commission filings from Merck and Gilead Sciences; White House statements; and contemporaneous reporting by Bloomberg and The Washington Post. The released agreements are materially redacted, so conclusions concerning exact revenue-sharing amounts and comparative obligations remain limited by the available record.
EN
Agricultural News
Food News
Industrial News
Cosmetic News
Pharmaceutical News
Science News
